677,436 results match your criteria Hormone Therapy


Pilot study of an artificial intelligence-based deep learning algorithm to predict time to castration-resistant prostate cancer for metastatic hormone-naïve prostate cancer.

Jpn J Clin Oncol 2022 Jun 25. Epub 2022 Jun 25.

Department of Urology, Osaka Rosai Hospital, Osaka, Japan.

The object in this study is to develop an artificial intelligence-based deep learning algorithm for prediction of time to castration-resistant prostate cancer by combined androgen blockade therapy in metastatic hormone-naïve prostate cancer. We included 180 metastatic hormone-naïve prostate cancer patients who initially received combined androgen blockade. We first evaluated whether time to castration-resistant prostate cancer was a significant prognostic factor. Read More

View Article and Full-Text PDF

Resynthesis of Transmasculine Voices to Assess Gender Perception as a Function of Testosterone Therapy.

J Speech Lang Hear Res 2022 Jun 24:1-16. Epub 2022 Jun 24.

Department of Biomedical Engineering, Boston University, MA.

Purpose: The goal of this study was to use speech resynthesis to investigate the effects of changes to individual acoustic features on speech-based gender perception of transmasculine voice samples following the onset of hormone replacement therapy (HRT) with exogenous testosterone. We hypothesized that mean fundamental frequency ( ) would have the largest effect on gender perception of any single acoustic feature.

Method: Mean , contour, and formant frequencies were calculated for three pairs of transmasculine speech samples before and after HRT onset. Read More

View Article and Full-Text PDF

Chinese herbal medicine for children with idiopathic short stature (ISS): A systematic review and meta-analysis.

PLoS One 2022 24;17(6):e0270511. Epub 2022 Jun 24.

Department of Pediatrics, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.

Background: Idiopathic short stature (ISS) describes a heterogeneous group of children of many unidentified causes of short stature presently without definitive therapy. Chinese herbal medicine (CHM) is an alternative and complementary treatment for children with ISS and has been widely used for ISS while the evidence of its effectiveness is controversial. We conducted this systematic review and meta-analysis in order to evaluate the efficacy of CHM for ISS. Read More

View Article and Full-Text PDF

Effects of dance therapy in women with breast cancer: A systematic review protocol.

PLoS One 2022 24;17(6):e0257948. Epub 2022 Jun 24.

Federal University of Pará (UFPA), Belém, Pará, Brazil.

Background: Cancer is an important public health problem with an increasing global incidence in the recent decades. Breast cancer has become the leading cause of death in women worldwide. Women suffering from breast cancer, as well as survivors, may experience some adverse effects of treatment-including cancer-related fatigue, sleep disorders, and pain-which may manifest alone or in combination with other symptoms. Read More

View Article and Full-Text PDF

Assessing Fertility Intentions in Patients Presenting for Gender-Affirming Surgery.

LGBT Health 2022 Jun 24. Epub 2022 Jun 24.

Center for Gender Surgery, Boston Children's Hospital, Boston, Massachusetts, USA.

For some transgender and gender-diverse (TGD) individuals, gender-affirming surgery may represent the last opportunity to engage in gamete banking (GB) and other forms of fertility preservation (FP). Previous research has assessed fertility intentions among TGD people initiating hormone therapy. The objective of this study was to describe the fertility intentions of patients seeking gender-affirming surgery. Read More

View Article and Full-Text PDF

Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy.

J Endocrinol Invest 2022 Jun 24. Epub 2022 Jun 24.

Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.

Purpose: This study aims to compare the accuracy of mean GH profile (GHP) < 2.5 ng/ml and single fasting GH (SGH) < 1 ng/ml in the evaluation of disease control in acromegaly patients during somatostatin receptor ligands (SRLs) therapy.

Methods: We retrospectively enrolled 100 acromegaly patients, 68 responder, and 32 partial responder to SRLs. Read More

View Article and Full-Text PDF

Androgens, aging, and prostate health.

Rev Endocr Metab Disord 2022 Jun 24. Epub 2022 Jun 24.

Department of Urology, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Due to late onset hypogonadism (LOH), there is an increased usage of testosterone replacement therapy (TRT) in the aging male population. Since prostate is a target organ for androgens and anti-androgenic strategies are used to treat and palliate benign prostate hyperplasia (BPH) and prostate cancer (PC), the prevalence of both increases with age, the possible influence of TRT on prostate health becomes highly relevant. The present review summarizes existing data on the associations between endogenous hormone concentrations and prostate growth and concludes that circulating concentrations of androgens do not appear to be associated with the risks of development of BPH or initiation or progression of PC. Read More

View Article and Full-Text PDF

Protein Tyrosine Phosphatase 1B Deficiency Improves Glucose Homeostasis in Insulin-Dependent Diabetes Mellitus Treated with Leptin.

Diabetes 2022 Jun 24. Epub 2022 Jun 24.

Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-Ward, Nagoya, 466-8550, Japan.

Leptin, a hormone secreted by adipocytes, exhibits therapeutic potential for the treatment of insulin-dependent diabetes mellitus (IDDM). Protein tyrosine phosphatase 1B (PTP1B) is a key enzyme that negatively regulates leptin receptor signaling. Here, the role of PTP1B in the treatment of IDDM was investigated using PTP1B deficient (KO) mice and a PTP1B inhibitor. Read More

View Article and Full-Text PDF

Ovarian Tissue-Based Hormone Replacement Therapy Recovers Menopause-Related Signs in Mice.

Yonsei Med J 2022 Jul;63(7):648-656

Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.

Purpose: In women, menopause manifests with a variety of symptoms related to sex-hormone deficiency. Supplementing steroid hormones with pharmacological drugs has been widely practiced. However, considering the possible complications associated with artificial hormone therapy, studies have been conducted to find an alternative to pharmacological hormone replacement therapy. Read More

View Article and Full-Text PDF

Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.

Cancer Med 2022 Jun 24. Epub 2022 Jun 24.

Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.

Introduction: Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti-oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented. Read More

View Article and Full-Text PDF

Association between the levels of serum free testosterone and lifestyle-related diseases in people living with HIV.

Curr HIV Res 2022 Jun 23. Epub 2022 Jun 23.

Department of Microbiology and Immunology, Teikyo University School of Medicine, Tokyo, Japan.

Background: Recently, male hypogonadism was reported to be prevalent in people living with HIV (PLWH), even in cases diagnosed based on the serum free testosterone level (fTST). However, studies on the management of PLWH, showing the relationship between male hypogonadism and lifestyle-associated diseases are sparse.

Objective: This study evaluated the relationship between serum fTST levels and lifestyle-related diseases in virologically stable PLWH. Read More

View Article and Full-Text PDF

GUIDANCE TO THE MATERNAL, FETAL AND NEONATAL MANAGEMENT OF RESISTANCE GRAVE'S DISEASE IN PREGNANCY.

Authors:
D V Das A Baro

Acta Endocrinol (Buchar) 2021 Oct-Dec;17(4):517-520

Gauhati Medical College and Hospital - Dept. of Endocrinology, Guwahati, Assam, India.

Resistant Graves' disease in pregnancy is a rare entity. The clinical situation poses immense difficulty to the treating endocrinologist and obstetrician in optimizing maternal and fetal heath. No guidelines till date are available to manage resistant Grave's disease in pregnancy. Read More

View Article and Full-Text PDF

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer.

Radiol Case Rep 2022 Sep 17;17(9):2996-2999. Epub 2022 Jun 17.

Unit of Diagnostic Imaging and Interventional Radiology, Fondazione Policlinico Campus Bio-Medico di Roma, Università Campus Bio-Medico di Roma, via Alvaro del Portillo 21, Rome 00128, Italy.

Several cases of cancer patients with 18-fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) evidence of metabolically active axillary lymph nodes after COVID-19 vaccination have been described, creating a diagnostic dilemma and sometimes leading to further unnecessary examinations. A 62-year-old male, diagnosed with prostate cancer, treated with hormone-therapy and radiotherapy of the prostate 2 years before, underwent fluorine-18 choline (F-FCH) PET/CT for restaging purpose, less than 3 weeks after he had received the second dose of the Pfizer BioNTech-BNT162b2 mRNA COVID-19 vaccine. This exam showed an increased F-FCH uptake and an enlargement of the left axillary, paratracheal, para-aortic, subcarinal, and hilar bilateral lymph nodes. Read More

View Article and Full-Text PDF
September 2022

Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia.

Mol Clin Oncol 2022 Jul 1;17(1):119. Epub 2022 Jun 1.

Oncology Center, International Medical Center, King Saud Bin Abdul Aziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, Jeddah 21423, Kingdom of Saudi Arabia.

The addition of palbociclib (a cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) among patients with hormone receptor-positive (HR) advanced breast cancer. The current study presents the local experience of using palbociclib at two cancer centers in Saudi Arabia. Electronic data of patients with metastatic HR and human epidermal growth factor receptor 2-negative breast cancer who progressed after prior ET and received at least one cycle of palbociclib plus ET, were retrospectively reviewed. Read More

View Article and Full-Text PDF

Intracranial Hypertension in a Transgender Man.

Neurol Clin Pract 2022 Jun;12(3):275-277

Hauenstein Neurosciences (KQ, SQ, AA), Mercy Health Saint Mary's; and Eye Plastic & Facial Cosmetic Surgery (AH), Grand Rapids, MI.

Objective: Case description of recurrent idiopathic intracranial hypertension (IIH) in a transgender man on gender-affirming hormone therapy.

Methods: Case report.

Results: A 24-year-old transmasculine patient (assigned female at birth), with a body mass index (BMI) of 37. Read More

View Article and Full-Text PDF

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury.

Pharmaceuticals (Basel) 2022 Jun 6;15(6). Epub 2022 Jun 6.

Department of Pharmacology & Toxicology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait.

Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type 2 diabetes mellitus. However, GLP-1 is rapidly degraded by dipeptdyl peptidase-IV (DPP-IV) to GLP-1 (9-36). Read More

View Article and Full-Text PDF

New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review.

Medicina (Kaunas) 2022 Jun 6;58(6). Epub 2022 Jun 6.

Obstetrics and Gynecology Unit, IRCCS San Raffaele Hospital, Vita-Salute University, 20132 Milan, Italy.

Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus and lower urinary tract. This condition is related to hypoestrogenism consequent to menopause onset but is also due to the hormonal decrease after adjuvant therapy for patients affected by breast cancer. Considering the high prevalence of VVA and the expected growth of this condition due to the increase in the average age of the female population, it is easy to understand its significant social impact. Read More

View Article and Full-Text PDF

Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review.

J Pers Med 2022 May 31;12(6). Epub 2022 May 31.

Faculty of Medicine, "Victor Babeş" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.

In the last decades, both animal and human studies have neglected female subjects with the aim of evading a theorized intricacy of feminine hormonal status. However, clinical experience proves that pharmacological response may vary between the two sexes since pathophysiological dissimilarities between men and women significantly influence the pharmacokinetics and pharmacodynamics of drugs. Sex-related differences in central nervous system (CNS) medication are particularly challenging to assess due to the complexity of disease manifestation, drugs' intricate mechanisms of action, and lack of trustworthy means of evaluating the clinical response to medication. Read More

View Article and Full-Text PDF

Risk of Depression during Menopause in Women from Poland, Belarus, Belgium, and Greece.

J Clin Med 2022 Jun 12;11(12). Epub 2022 Jun 12.

General Hospital Kavala Greece, 65500 Kavala, Greece.

Introduction: Menopause is a physiological period in a woman's life, but it is often accompanied by symptoms that affect mental well-being and general health, including a tendency for depression.

Aim Of The Study: To evaluate the predisposition to the symptoms of depression in women from Poland, Belarus, Belgium, and Greece.

Material And Methods: the method of diagnostic survey was used, and the research tools were: The Menopause Rating Scale, the Kupperman Index, Beck Depression Inventory, and a self-made survey questionnaire. Read More

View Article and Full-Text PDF

AB186 Inhibits Migration of Triple-Negative Breast Cancer Cells and Interacts with α-Tubulin.

Int J Mol Sci 2022 Jun 20;23(12). Epub 2022 Jun 20.

CNRS, CRAN, Université de Lorraine, F-54000 Nancy, France.

Breast cancer is one of the leading causes of cancer-related death among females worldwide. A major challenge is to develop innovative therapy in order to treat breast cancer subtypes resistant to current treatment. In the present study, we examined the effects of two Troglitazone derivatives Δ2-TGZ and AB186. Read More

View Article and Full-Text PDF

Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens.

Int J Mol Sci 2022 Jun 18;23(12). Epub 2022 Jun 18.

Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.

Breast cancer therapies have made significant strides in improving survival for patients over the past decades. However, recurrence and drug resistance continue to challenge long-term recurrence-free and overall survival rates. Mounting evidence supports the cancer stem cell model in which the existence of a small population of breast cancer stem cells (BCSCs) within the tumor enables these cells to evade conventional therapies and repopulate the tumor, giving rise to more aggressive, recurrent tumors. Read More

View Article and Full-Text PDF

Heterozygous Variants in Idiopathic Short Stature.

Genes (Basel) 2022 Jun 15;13(6). Epub 2022 Jun 15.

Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, UMC, 1000 Ljubljana, Slovenia.

Heterozygous variants in the gene, which encodes the B-type natriuretic peptide receptor (NPR-B), a regulator of skeletal growth, were reported in 2-6% cases of idiopathic short stature (ISS). Using next-generation sequencing (NGS), we aimed to assess the frequency of variants in our study cohort consisting of 150 children and adolescents with ISS, describe the phenotypic spectrum with a growth pattern including birth data, and study the response to growth hormone (GH) treatment. A total of ten heterozygous pathogenic/likely pathogenic variants and two heterozygous variants of uncertain significance were detected in twelve participants (frequency of causal variants: 10/150, 6. Read More

View Article and Full-Text PDF

Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.

Biology (Basel) 2022 Jun 3;11(6). Epub 2022 Jun 3.

Department of General Medicine, Sapporo Medical University, S1 W17, Sapporo 060-8556, Japan.

The field of natriuretic peptides (NPs) as an endocrine hormone has been developing since 1979. There are three peptides in humans: atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which bind to the guanylyl cyclase-A (GC-A) receptor (also called natriuretic peptide receptor-A (NPR-A)), and C-type natriuretic peptide (CNP), which binds to the GC-B receptor (also called the NPR-B) and then synthesizes intracellular cGMP. GC-A receptor stimulation has natriuretic, vasodilatory, cardiorenal protective and anti-renin-angiotensin-aldosterone system actions, and GC-B receptor stimulation can suppress myocardial fibrosis and can activate bone growth before epiphyseal plate closure. Read More

View Article and Full-Text PDF

Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis.

Cells 2022 Jun 12;11(12). Epub 2022 Jun 12.

Innate Immunity Laboratory, Immunology Program, Biomedical Sciences Institute, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile.

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) and can be treated with glucocorticoids (GC), although some patients are unresponsive to this therapy. The transcription factor LRH-1/ is critical to intestinal cortisol production (intestinal steroidogenesis), being reduced in UC patients. However, the relationship between LRH-1 expression and distribution with altered corticosteroid responses is unknown. Read More

View Article and Full-Text PDF

Overcoming the Limitations of Stem Cell-Derived Beta Cells.

Biomolecules 2022 Jun 9;12(6). Epub 2022 Jun 9.

Koltzov Institute of Developmental Biology of Russian Academy of Sciences, 119334 Moscow, Russia.

Great advances in type 1 diabetes (T1D) and type 2 diabetes (T2D) treatment have been made to this day. However, modern diabetes therapy based on insulin injections and cadaveric islets transplantation has many disadvantages. That is why researchers are developing new methods to regenerate the pancreatic hormone-producing cells in vitro. Read More

View Article and Full-Text PDF

Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study.

Cancers (Basel) 2022 Jun 10;14(12). Epub 2022 Jun 10.

Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy.

Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, is approved for GCTB. Data on serum bone turnover marker (sBTM) changes are lacking. Read More

View Article and Full-Text PDF

Why Does Psychotherapy Work and for Whom? Hormonal Answers.

Biomedicines 2022 Jun 9;10(6). Epub 2022 Jun 9.

Department of Psychology, University of Haifa, Haifa 31905, Israel.

The questions of for whom and why psychotherapy is effective have been the focus of five decades of research. Most of this knowledge is based on self-report measures. Following the biopsychosocial model of mental disorders, this article explores the potential of hormones in answering these questions. Read More

View Article and Full-Text PDF

Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein.

Biomedicines 2022 Jun 3;10(6). Epub 2022 Jun 3.

Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.

Estrogen promotes the development and survival of the majority of breast cancers (BCs). Aromatase is the rate-limiting enzyme in estrogen biosynthesis, and it is immensely expressed in both cancerous and non-cancerous breast tissues. Endocrine therapy based on estrogen blockade, by aromatase inhibitors, has been the mainstay of BC treatment in post-menopausal women; however, resistance to hormone therapy is the leading cause of cancer death. Read More

View Article and Full-Text PDF

Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis".

Breast Cancer Res Treat 2022 Jun 24. Epub 2022 Jun 24.

Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.

View Article and Full-Text PDF

Structural insights into ligand recognition and selectivity of somatostatin receptors.

Cell Res 2022 Jun 23. Epub 2022 Jun 23.

State Key Laboratory of Drug Research and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Somatostatin receptors (SSTRs) play versatile roles in inhibiting the secretion of multiple hormones such as growth hormone and thyroid-stimulating hormone, and thus are considered as targets for treating multiple tumors. Despite great progress made in therapeutic development against this diverse receptor family, drugs that target SSTRs still show limited efficacy with preferential binding affinity and conspicuous side-effects. Here, we report five structures of SSTR2 and SSTR4 in different states, including two crystal structures of SSTR2 in complex with a selective peptide antagonist and a non-peptide agonist, respectively, a cryo-electron microscopy (cryo-EM) structure of G-bound SSTR2 in the presence of the endogenous ligand SST-14, as well as two cryo-EM structures of G-bound SSTR4 in complex with SST-14 and a small-molecule agonist J-2156, respectively. Read More

View Article and Full-Text PDF